Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENESTop: Treatment-free Remission in CML Patients After Sustained MR4.5 on Nilotinib
NCT01698905Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2012
- Primary completion
- Nov 2015
- Countries
- 18
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Novartis. Primary endpoint: Percentage of Participants in Treatment-Free Remission (TFR) at 48 weeks. Started Dec 2012; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01698905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01698905.